Status: Not yet recruiting
Psilocybin as a Novel Therapy for Residual Anhedonia
The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).
Participants needed: 90
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: NYU Langone HealthUpdated: May 27, 2026Locations: 1
Eligibility criteria
Age between 18 and 65 years [+8]
Inability to speak and understand English sufficiently to complete informed cons... [+12]